NBIX Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$135.99 |
| 52 Week High | US$148.37 |
| 52 Week Low | US$89.04 |
| Beta | 0.28 |
| 1 Month Change | -1.34% |
| 3 Month Change | -4.33% |
| 1 Year Change | 34.59% |
| 3 Year Change | 43.92% |
| 5 Year Change | 72.20% |
| Change since IPO | 987.92% |
Recent News & Updates
Recent updates
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Apr 25Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31
Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Jan 07Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet
Mar 08Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Dec 08Neurocrine initiated Equal Weight at Wells Fargo despite upcoming catalysts
Sep 26Neurocrine to acquire U.K.-based biotech Diurnal
Aug 30Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter phase 2 trial
Aug 05Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly
Jul 26Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares
Jul 19Shareholder Returns
| NBIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.0% | -0.2% | 2.9% |
| 1Y | 34.6% | -1.0% | 22.2% |
Return vs Industry: NBIX exceeded the US Biotechs industry which returned -1% over the past year.
Return vs Market: NBIX exceeded the US Market which returned 22.2% over the past year.
Price Volatility
| NBIX volatility | |
|---|---|
| NBIX Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NBIX has not had significant price volatility in the past 3 months.
Volatility Over Time: NBIX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,400 | Kevin Gorman | www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.
Neurocrine Biosciences, Inc. Fundamentals Summary
| NBIX fundamental statistics | |
|---|---|
| Market cap | US$13.68b |
| Earnings (TTM) | US$249.70m |
| Revenue (TTM) | US$1.89b |
54.8x
P/E Ratio7.2x
P/S RatioIs NBIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBIX income statement (TTM) | |
|---|---|
| Revenue | US$1.89b |
| Cost of Revenue | US$604.70m |
| Gross Profit | US$1.28b |
| Other Expenses | US$1.03b |
| Earnings | US$249.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 2.48 |
| Gross Margin | 67.96% |
| Net Profit Margin | 13.23% |
| Debt/Equity Ratio | 7.6% |
How did NBIX perform over the long term?
See historical performance and comparison